Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Everyman reports strong first half as profits surge

(Sharecast News) - Everyman Media's share price jumped on Monday after the upmarket cinema chain delivered a positive trading update for the first half, as the bottom line was boosted by a surge in revenues and margin improvements. Group revenues totalled £56.5m over the six months to 3 July, up 21% year-on-year, helped by a 15% annual increase in admissions to 2.2m, a 6% increase in the average ticket price and a 5.9% increase in the amount spent on food and beverages.

This helped grow EBITDA by 33% on last year to £8.2m, which broker Canaccord Genuity said implied a margin increase of 130 basis points to 14.5%.

Everyman, which operates 48 cinemas following the most recent opening in Brentford in March, now has a 5.8% share of the UK cinema market, up from 5.6% at the same point last year.

The company said it plans to open one more site this year, in Bayswater, with two additional venues earmarked for 2026.

"Our performance in H1 reflects the successful execution of our strategy, with growth across all key metrics and ongoing delivery of our measured expansion programme. This is driven by Everyman's unique brand of high-quality, experience-led cinema," said chief executive Alex Scrimgeour.

"We look forward to building on this momentum in the second half of the year."

The company said it is currently trading in line with the board's expectations for the full year despite the "challenging economic environment".

Shares were up nearly 5% at 42.95p by 0959 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.